MXPA05012314A - Radical separador para peptido modificado con polietilenglicol. - Google Patents

Radical separador para peptido modificado con polietilenglicol.

Info

Publication number
MXPA05012314A
MXPA05012314A MXPA05012314A MXPA05012314A MXPA05012314A MX PA05012314 A MXPA05012314 A MX PA05012314A MX PA05012314 A MXPA05012314 A MX PA05012314A MX PA05012314 A MXPA05012314 A MX PA05012314A MX PA05012314 A MXPA05012314 A MX PA05012314A
Authority
MX
Mexico
Prior art keywords
moiety
poly
ethylene glycol
spacer moiety
modified peptides
Prior art date
Application number
MXPA05012314A
Other languages
English (en)
Inventor
Christopher P Holmes
Original Assignee
Affymax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Inc filed Critical Affymax Inc
Publication of MXPA05012314A publication Critical patent/MXPA05012314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)

Abstract

La presente invencion se refiere a un compuesto que comprende un radical peptido, un radical separador y un radical polimero soluble en agua, como un radical polietilenglicol; el radical separador se encuentra entre el radical peptido y el radical polimero soluble en agua; el radical separador tiene la estructura: -NH-(CH2)(-[O-(CH2)(](-O(-(CH2)(-Y-, en donde (, (, (, ( y ( son cada uno enteros cuyos valores se seleccionan en forma independiente.
MXPA05012314A 2003-05-12 2004-05-12 Radical separador para peptido modificado con polietilenglicol. MXPA05012314A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46999603P 2003-05-12 2003-05-12
PCT/US2004/014887 WO2004100997A2 (en) 2003-05-12 2004-05-12 Spacer moiety for poly(ethylene glycol) -modified peptides

Publications (1)

Publication Number Publication Date
MXPA05012314A true MXPA05012314A (es) 2006-04-18

Family

ID=33452348

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012314A MXPA05012314A (es) 2003-05-12 2004-05-12 Radical separador para peptido modificado con polietilenglicol.

Country Status (16)

Country Link
US (2) US7919118B2 (es)
EP (2) EP2204193A3 (es)
JP (2) JP2007500218A (es)
KR (1) KR101160611B1 (es)
CN (1) CN1849141A (es)
AU (1) AU2004238364A1 (es)
BR (1) BRPI0411166A (es)
CA (1) CA2525399A1 (es)
EA (1) EA010015B1 (es)
IL (1) IL171885A0 (es)
IS (1) IS8168A (es)
MX (1) MXPA05012314A (es)
NO (1) NO20055848L (es)
NZ (2) NZ563042A (es)
WO (1) WO2004100997A2 (es)
ZA (1) ZA200509970B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
ES2323465T3 (es) * 2003-05-12 2009-07-16 Affymax, Inc. Peptidos novedosos que se unen al receptor de la eritropoyetina.
WO2004101600A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
FR2857875A1 (fr) * 2003-07-25 2005-01-28 Univ Reims Champagne Ardenne Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers
US20080026995A1 (en) * 2003-07-25 2008-01-31 Ac Immune Sa Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20070275007A1 (en) * 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP2035041B1 (en) 2006-06-30 2020-01-08 Syntab Therapeutics GmbH Conjugates for innate immunotherapy of cancer
WO2008100288A2 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
EP2118127A4 (en) * 2007-01-31 2010-12-01 Affymax Inc NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
WO2009027844A2 (en) * 2007-05-25 2009-03-05 Celtic Pharma Management L.P. Crf conjugates with extended half-lives
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
WO2009002947A2 (en) * 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
WO2009058291A2 (en) * 2007-10-31 2009-05-07 University Of Alabama In Huntsville Controlled molecular weight amino acid polymers having functionalizable backbones and end groups and processes for preparing the same
BRPI0821029A2 (pt) * 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
RU2010148803A (ru) * 2008-04-30 2012-06-10 Ньютрон Роу (Bm) Способы применения кортикотропин-рилизинг фактора для лечения рака
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
UA103104C2 (ru) 2009-07-22 2013-09-10 Ипсен Фарма С.А.С. Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
ES2632164T3 (es) 2010-07-06 2017-09-11 Augustinus Bader Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
US9463255B1 (en) * 2011-09-29 2016-10-11 Stc.Unm Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
WO2016205488A1 (en) * 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
KR102142978B1 (ko) * 2017-12-18 2020-08-11 경희대학교 산학협력단 신규 페길화 서브스턴스 ｐ
EP3572434B1 (en) 2018-05-25 2022-08-17 UPM-Kymmene Corporation Nanofibrillar cellulose hydrogel

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
ES2085297T3 (es) 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5292654A (en) * 1990-12-13 1994-03-08 Whitehead Institute For Biomedical Research Mutant EPO receptor and uses therefor
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
EP1510524A3 (en) 1995-06-07 2006-06-07 Ortho Pharmaceutical Corporation Compounds and peptides that bind to the erythropoietin receptor
ZA964814B (en) 1995-06-07 1998-02-09 Glaxo Group Ltd Peptides and compounds that bind to a receptor.
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
WO1998005363A2 (en) 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6221608B1 (en) 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US6211608B1 (en) * 1998-06-11 2001-04-03 Micron Technology, Inc. Field emission device with buffer layer and method of making
JP5183836B2 (ja) 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
EP1008355A1 (en) 1998-12-08 2000-06-14 Debio Recherche Pharmaceutique S.A. Method for identifying or analyzing polymer linkage sites on macromolecules using amino acid report binding
EP1107998B1 (en) 1998-08-28 2004-02-04 Gryphon Sciences Method for the preparation of polyamide chains of precise length, their conjugates with proteins
TWI257394B (en) * 1998-10-23 2006-07-01 Kirin Amgen Inc Thrombopoietic compounds
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE69929464T2 (de) * 1998-11-17 2006-09-07 Smithkline Beecham Corp. Zyklische polyamine zur behandlung der thrombozytopenie
EP1146860A4 (en) * 1999-01-08 2002-07-03 Emisphere Tech Inc POLYMER DRUG DELIVERY SYSTEMS AND COMPOUNDS
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AUPQ873300A0 (en) 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
ES2279769T3 (es) * 1999-09-24 2007-09-01 Smithkline Beecham Corporation Mimeticos de trombopoyetina.
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US6858630B2 (en) 1999-12-06 2005-02-22 Smithkline Beecham Corporation Naphthimidazole derivatives and their use as thrombopoietin mimetics
EP1334118A4 (en) * 2000-03-21 2005-10-05 Wisconsin Alumni Res Found METHOD AND RESPONSE FOR REGULATING CELLULAR RESPONSE IN BIOLOGICAL SYSTEMS
US6777387B2 (en) * 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
EP1525889A1 (en) * 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
AU7490401A (en) * 2000-05-26 2001-12-11 Ortho Mcneil Pharm Inc Neuroprotective peptides
CZ2003311A3 (cs) * 2000-08-02 2004-04-14 Ortho-Mcneil Pharmaceutical, Inc. Protivirová a protinádorová terapie za použití erythropoetinu
CN1454097A (zh) * 2000-09-08 2003-11-05 格莱风治疗公司 聚合物修饰的合成的蛋白质类
MXPA03005406A (es) * 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
AU2002251988A1 (en) * 2001-02-20 2002-09-04 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US7229810B2 (en) * 2001-06-28 2007-06-12 Mountain View Pharmaceuticals, Inc. Polymer conjugates of proteinases
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050501A (en) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
RS20050502A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
ES2323465T3 (es) * 2003-05-12 2009-07-16 Affymax, Inc. Peptidos novedosos que se unen al receptor de la eritropoyetina.
ES2395413T3 (es) * 2003-05-12 2013-02-12 Affymax, Inc. Péptidos que se unen al receptor de eritropoyetina
WO2004101600A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.

Also Published As

Publication number Publication date
CN1849141A (zh) 2006-10-18
EA010015B1 (ru) 2008-06-30
US20120115796A1 (en) 2012-05-10
EA200501800A1 (ru) 2006-08-25
US20070032408A1 (en) 2007-02-08
US7919118B2 (en) 2011-04-05
JP2012140466A (ja) 2012-07-26
EP1628686A2 (en) 2006-03-01
BRPI0411166A (pt) 2006-07-18
IS8168A (is) 2005-12-02
NZ543934A (en) 2008-06-30
WO2004100997A2 (en) 2004-11-25
NZ563042A (en) 2008-09-26
US8592365B2 (en) 2013-11-26
CA2525399A1 (en) 2004-11-25
IL171885A0 (en) 2006-04-10
AU2004238364A1 (en) 2004-11-25
KR20060023123A (ko) 2006-03-13
ZA200509970B (en) 2006-11-29
NO20055848L (no) 2006-02-13
EP2204193A3 (en) 2010-08-18
KR101160611B1 (ko) 2012-06-28
JP2007500218A (ja) 2007-01-11
EP2204193A2 (en) 2010-07-07
WO2004100997A3 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
MXPA05012314A (es) Radical separador para peptido modificado con polietilenglicol.
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
ZA986281B (en) Films produced from substantially linear homogeneous olefin polymer compositions.
GB0322643D0 (en) High performance jack for telecommunication applications
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
SV2004001432A (es) 2-tio-3,5-diciano-4-4fenil-6-aminopiridinas substituidas y su uso ref. lea 35 640-sv
AU2001280920A1 (en) Mutant trichoderma reesei egiii cellulases, dna encoding such egiii compositions and methods for obtaining same
AU2673901A (en) A reinforcing structure for stiff composite articles
PT1133586E (pt) Modulo de electrolisador de elevada pressao
ATE286740T1 (de) Zyklische peptide mit breitspektrum antimikrobieller aktivität
TW200728279A (en) Polymeric carbazole compounds
AU2208499A (en) Grafted poly(ethylene oxide) compositions
EP1988099A3 (en) Bacillus thuringiensis insecticidal proteins
EP0651022A3 (en) Stubborn elastomers from organopolysiloxane compositions.
DE69632922D1 (de) Fluor-enthaltende elastomerzusammensetzungen
DE69720423D1 (de) Hochdruck-, Kraftstoffförderpumpe
BRPI0415287A (pt) macrÈmeros insaturados para estabilizadores pré-formados e polióis poliméricos
WO2008095004A3 (en) Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
AU2002259281A1 (en) Antibodies specific for poly(ethylene glycol)
AU2020400A (en) Ethylene alpha-olefin elastomeric polymer compositions having improved extrusionprocessibility
WO2004112703A3 (en) Interleukin-21 analogs
SG38904A1 (en) High performance polymer compositions
PL377763A1 (pl) Peptydy, które hamują angiogenezę, migrację komórek, naciekanie komórkowe i proliferację komórkową oraz kompozycje zawierające te peptydy i ich zastosowania
MX9703702A (es) Adhesivos mejorados de laminacion basados en isocianato.
WO2000014206A3 (en) Mutant egiii cellulases, dna encoding such egiii compositions and methods for obtaining same

Legal Events

Date Code Title Description
FG Grant or registration